Sale of Intellectual Property in Exchange for Cancellation of the Boston Scientific Notes
|9 Months Ended|
Sep. 30, 2015
|Related Party Transactions [Abstract]|
|Sale of Intellectual Property in Exchange for Cancellation of the Boston Scientific Notes||
In March 2014, the Company entered into an Asset Purchase Agreement (the BSC Purchase Agreement) with Boston Scientific. Pursuant to the BSC Purchase Agreement, Boston Scientific purchased from the Company certain MRI-safety
technology for implantable medical leads (the Transferred Intellectual Property) for an aggregate purchase price of $4,338,601. The Transferred Intellectual Property includes some, but not all, of the intellectual property the Company previously licensed exclusively to Boston Scientific within the fields of neuromodulation and implantable medical leads for cardiac applications. The purchase price was satisfied through the cancellation of three convertible notes payable issued by the Company to Boston Scientific, which were scheduled to mature in 2014, in the aggregate principal amount of $4,338,601 (the Boston Scientific Notes). Accordingly, all obligations of the Company under the Boston Scientific Notes were discharged and the liens that secured the Companys obligations under the Boston Scientific Notes were terminated and released. The Company recorded a gain in its condensed consolidated statement of operations for the nine months ended September 30, 2014, equal to the aggregate purchase price for the assets sold under the BSC Purchase Agreement.
In connection with the BSC Purchase Agreement, the parties entered into a license agreement pursuant to which Boston Scientific granted the Company an exclusive, royalty-free, fully paid up, irrevocable, worldwide license to the Transferred Intellectual Property, with the right to sublicense, within fields of use other than neuromodulation and implantable medical leads for cardiac applications.
In addition, Boston Scientific and the Company entered into amendments to their pre-existing development and license agreements (the Pre-existing Agreements), in the fields of neuromodulation and implantable medical leads for cardiac applications, to eliminate the milestone-based payments and royalties provided under those agreements. As such, the Company is no longer entitled to receive any potential future milestone-based payments or royalties under its development and license agreements with Boston Scientific.
The transactions completed under the terms of the BSC Purchase Agreement do not impact the Companys ability to continue to commercialize its ClearPoint system or to continue the development of its ClearTrace system.
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
Reference 1: http://www.xbrl.org/2003/role/presentationRef